Remove Engineer Remove In-Vitro Remove In-Vivo Remove Reagent
article thumbnail

Turning science into business: AnĀ optimised alternative to antibodies

Drug Discovery World

As the industry moves to reduce the use of animals in research and testing, aptamers also support here, as they are discovered, developed, and manufactured entirely in vitro , removing the need for animals in antibody discovery processes. Optimer binders are engineered to overcome these problems. To what do you attribute your success?

article thumbnail

The evolution of assays for immuno-oncology research

Drug Discovery World

Sophisticated and continually evolving preclinical IO models (in vivo and in vitro) are particularly helpful in defining translational therapeutic strategies and understanding the efficacy of combination immunotherapies and refractory cancers, and in the identification of novel prognostic biomarkers.

article thumbnail

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. However, this has since changed, and now, transitioning between academia and industry has become more commonplace. Key Moments.